Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Recurrent or Residual High Grade Meningioma
NCT03279692Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2017
- Primary completion
- Sep 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in meningioma, sponsored by Massachusetts General Hospital. Started Nov 2017; status: active, not recruiting.
02
Drugs
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT03279692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279692.